Patent intelligence · US
US 11207299
Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
Patent details — US 11207299
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 28, 2021
- Expiration
- Dec 23, 2041
- Applicant
- Travere Therapeutics, Inc.
- Claims
- 22
- CPC classes
- A61K, A61K31/422, A61K45/06, A61K9/00
Quick answer
US 11207299 (Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases) is held by Travere Therapeutics, Inc.. Status: granted. Granted Dec 28, 2021. Expires Dec 23, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Travere Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K31/422, A61K45/06, A61K9/00, A61K9/0053, A61P
Frequently asked questions
What is US patent 11207299?
US 11207299 (Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases) is held by Travere Therapeutics, Inc.. Status: granted. Granted Dec 28, 2021. Expires Dec 23, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11207299?
Travere Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 11207299 expire?
Our index shows an expiration date of Dec 23, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.